Recent advances in pharmacogenomics for improved drug therapy.
Journal name: World Journal of Pharmaceutical Research
Original article title: Pharmacogenomics biomarkers for improved drug therapy recent progress and future development
The WJPR includes peer-reviewed publications such as scientific research papers, reports, review articles, company news, thesis reports and case studies in areas of Biology, Pharmaceutical industries and Chemical technology while incorporating ancient fields of knowledge such combining Ayurveda with scientific data.
This page presents a generated summary with additional references; See source (below) for actual content.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Mansi Poptani, Nandnee Singh Rajpoot, Khushbu solanki, Manish Upadhyay, Sameer Pandey and Pushpendra Kumar Khangar
Download the PDF file of the original publication
World Journal of Pharmaceutical Research:
(An ISO 9001:2015 Certified International Journal)
Full text available for: Pharmacogenomics biomarkers for improved drug therapy recent progress and future development
Source type: An International Peer Reviewed Journal for Pharmaceutical and Medical and Scientific Research
Doi: 10.20959/wjpr20225-23927
Copyright (license): WJPR: All rights reserved
Summary of article contents:
Introduction
Pharmacogenomic research seeks to understand individual variations in drug responses, with an emphasis on how specific genetic markers, known as pharmacogenomic biomarkers, can predict drug efficacy and adverse reactions. Variability in patient responses to medications can often lead to serious health risks, including adverse drug reactions (ADRs) and under-treatment. On average, genetic factors account for approximately 20-30% of the variability in drug response. The liver, largely driven by polymorphic enzymes from the cytochrome P450 (CYP) superfamily, plays a central role in drug metabolism, prompting interest in harnessing genetic insights to improve clinical pharmacotherapy and reduce adverse outcomes.
The Role of Pharmacogenomic Biomarkers
Pharmacogenomic biomarkers can be classified into two main categories: germline biomarkers, which affect systemic pharmacokinetics and pharmacodynamics, and somatic biomarkers, which influence how cancers react to treatments. Importantly, advancements in genetics have revealed a wealth of genomic variations that contribute to drug metabolism, establishing a foundation for personalized medicine. For instance, specific genetic variants in drug-metabolizing enzymes have profound implications for treatment outcomes. Examples such as variations in the CYP2D6 gene illustrate this, with metabolizer status dramatically affecting the efficacy and safety of medications like codeine.
Implications of Rare Genetic Variants
Research demonstrates that while common genetic variants are crucial for understanding drug responses, rare genetic variants significantly impact pharmacokinetics and treatment responses. Studies have indicated that these rare variants, though less frequent in the general population, can have considerable effects on drug behavior. For example, the prevalence of the reduced functionality allele CYP2B6*6 in certain populations led to unexpected adverse reactions when standard treatments were implemented. This highlights the necessity of considering population-specific genetic landscapes to optimize treatment strategies in diverse demographic contexts.
Technological Advances and Their Impact
Recent technological advancements in genomic sequencing, particularly next-generation sequencing (NGS), enable more comprehensive analyses of genetic variants, including those that were previously difficult to detect. NGS provides insights into both somatic cancer genomes and rare genetic variations that can inform personalized medicine approaches. However, challenges remain, particularly in accurately interpreting the functional effects of numerous identified genetic variants. Emerging technologies like long-read sequencing and synthetic long-reads offer promising methods to advance our capabilities in pharmacogenomic research and application.
Conclusion
In conclusion, pharmacogenomic data is crucial for tailoring effective treatment regimens, especially within oncology; however, broader integration of these insights into clinical practice remains limited. The ongoing exploration of pharmacogenomic biomarkers across various therapeutic domains aims to ensure patients receive drugs that are safer and more effective. Future efforts should focus on addressing the barriers to application, improving understanding of genetic variability, and promoting the implementation of precision medicine to enhance patient outcomes in diverse healthcare settings.
FAQ section (important questions/answers):
What is pharmacogenomics and its significance in drug therapy?
Pharmacogenomics studies how genetic variations affect individuals' responses to drugs, allowing personalized medicine approaches. It enables predictions of drug responses, guiding drug selection and dosing to improve treatment efficacy and minimize adverse effects.
How do pharmacogenomic biomarkers improve patient outcomes?
Pharmacogenomic biomarkers help predict drug efficacy and risk of adverse drug reactions, thus allowing for tailored therapy. This personalized approach improves treatment outcomes and reduces the likelihood of adverse effects associated with certain medications.
What role do genetic polymorphisms play in drug response variability?
Genetic polymorphisms contribute to about 20-30% of the variability in drug response among individuals. These variations can affect drug metabolism and effectiveness, influencing how patients respond to specific medications.
What are germline and somatic biomarkers in pharmacogenomics?
Germline biomarkers are inherited genetic variations affecting systemic drug response, while somatic biomarkers are acquired changes in tumor cells that influence drug effectiveness, particularly in cancer therapies.
Why are rare genetic variants important in pharmacogenomics?
Rare genetic variants, which occur in less than 1% of the population, can significantly influence drug metabolism and response. Understanding these variants is crucial for precise medication management and patient care.
What advances are expected in pharmacogenomic technology?
Emerging technologies like next-generation sequencing (NGS) and long-read sequencing will enhance the identification of genetic variants, improving the accuracy of pharmacogenomic predictions and facilitating personalized medicine approaches.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “Recent advances in pharmacogenomics for improved drug therapy.”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Drug:
Drugs are substances used to diagnose, treat, or prevent diseases. In pharmacogenomics, understanding how genetic differences affect drug metabolism and response is crucial for developing therapies that can be customized for diverse populations, ensuring both efficacy and safety in treatments.
2) Cancer:
Cancer is a disease characterized by uncontrolled cell growth due to genetic mutations. Identifying genetic changes in tumors can lead to targeted therapies, improving patient prognosis. Pharmacogenomics aims to tailor treatment strategies based on individual genetic profiles, making therapy more effective and personalized.
3) Mutation:
A mutation is a change in the DNA sequence that can affect gene function and lead to variations among individuals. In pharmacogenomics, mutations play a crucial role in determining how a patient metabolizes drugs, thereby influencing therapeutic effectiveness and susceptibility to adverse drug reactions.
4) Toxicity:
Toxicity refers to the degree to which a substance can harm an organism. In pharmacology, understanding the genetic basis of drug toxicity helps to predict adverse effects in individuals, allowing for personalized dosing regimens to minimize risk. Pharmacogenomic testing can guide safer medication choices.
5) Disease:
Diseases are pathological conditions that can variously affect bodily functions. Understanding the genetic underpinnings of diseases through pharmacogenomics facilitates the development of personalized treatments, which can lead to improved patient outcomes by addressing the specific genetic factors influencing each disease.
6) Activity:
Activity in pharmacogenomics usually refers to the biological or therapeutic efficacy of a drug within the body. Differences in genetic makeups can influence the activity of drug-metabolizing enzymes, which in turn affects drug response, effectiveness, and the likelihood of experiencing side effects.
7) Developing:
Developing refers to the process of evolving or creating new therapeutic methods or drugs. In pharmacogenomics, this process involves ongoing research to identify genetic markers that can inform treatment decisions, leading to the advancement of personalized medicine focused on optimizing therapy for individual patients.
8) Knowledge:
Knowledge encompasses the understanding gained through research and experience. In pharmacogenomics, knowledge about the genetic factors influencing drug response is vital for guiding healthcare practitioners in selecting appropriate therapies and dosage, improving patient outcomes through individualized treatment strategies.
9) Medicine:
Medicines are compounds administered for therapeutic purposes. In pharmacogenomics, knowledge of genetic variability in drug responses helps optimize treatment plans, ensuring that the administered medicines are not only effective but also safe, thereby improving overall healthcare outcomes.
10) Death:
Death, in the context of pharmacology, highlights the severe consequences of inadequate drug responses, including adverse drug reactions and ineffective treatments. By employing pharmacogenomic strategies, healthcare providers can better predict and prevent fatal outcomes, enhancing patient safety and improving overall therapeutic effectiveness.
11) Line:
Line in this context can refer to the lineage or genetic inheritance patterns that affect pharmacogenomic outcomes. Understanding family histories of drug response can guide personalized treatment strategies, demonstrating the significance of genetic backgrounds in determining individual pharmacological responses.
12) Pharmacological:
Pharmacological pertains to the study and application of drugs. In pharmacogenomics, pharmacological knowledge is essential for understanding how drugs interact with the genetic profiles of individuals, thereby maximizing drug efficacy and minimizing side effects through personalized medication strategies.
13) Chemotherapy:
Chemotherapy is a type of cancer treatment that uses drugs to kill or slow the growth of cancer cells. Pharmacogenomics can enhance chemotherapy by predicting which patients are likely to respond well to certain drugs, enabling tailored treatment regimens that minimize toxicity and improve efficacy.
14) Science (Scientific):
Science embodies the rigorous study of structures and behaviors of the physical and natural world through observation and experimentation. In pharmacogenomics, scientific inquiry is essential to decipher genetic influences on drug metabolism, guiding advancements in personalized medicine and enhancing patient care.
15) Sagar (Sagár):
Sagar refers to a geographic location, specifically a city in India. The mention of Sagar in pharmacogenomic contexts may indicate research institutions or collaborations focusing on the study of pharmacogenomics and personalized medicine, contributing to advancements in healthcare in that region.
16) Kumar:
Kumar is a common surname in India and may refer to an author or researcher in the field of pharmacogenomics, such as Pushpendra Kumar Khangar. Researchers bearing this name are likely contributing to advancements in personalized medicine through genomic studies that influence drug therapy.
17) Field:
Field denotes a specialized area of study or professional practice. In pharmacogenomics, this field focuses on understanding the relationship between genetic variations and drug responses, paving the way for personalized medicine approaches that tailor treatments to individual genetic profiles.
18) Pose:
Pose refers to presenting a challenge or problem. In the context of pharmacogenomics, the variability in drug response due to genetic differences poses significant challenges for healthcare providers, necessitating strategies to tailor treatments effectively and minimize adverse drug reactions in diverse patient populations.
19) Accumulation (Accumulating, Accumulate):
Accumulation in pharmacogenomics may refer to the gathering of genetic mutations or polymorphisms over time that contribute to disease pathology or drug response variability. Understanding these accumulations helps researchers identify risk factors and develop interventions tailored to specific genetic profiles.
20) Performance:
Performance in the context of pharmacogenomics refers to the effectiveness of drug treatments based on individual genetic makeups. Evaluating the performance of pharmacogenomic strategies aids in advancing personalized medicine, ensuring optimal drug response and minimizing adverse effects through tailored approaches.
21) Measurement:
Measurement involves the quantitative assessment of parameters or attributes. In pharmacogenomics, measurement of genetic variants and their impact on drug responses is essential for evaluating treatment efficacy, determining genetic predispositions, and guiding personalized therapy decisions.
22) Perception:
Perception in pharmacogenomics refers to how genetic information regarding drug metabolism influences healthcare providers' and patients' understanding of treatment options. Increased awareness and perception of pharmacogenomic data facilitate the integration of personalized medicine into clinical practice, enhancing individualized patient care.
23) Depression:
Depression refers to a mental health disorder characterized by persistent sadness and loss of interest. Certain drugs used to treat depression can have varying efficacy based on genetic variations, highlighting the importance of pharmacogenomics in guiding effective individualized treatment plans.
24) Substance:
Substance refers to any material with a definite composition. Its relevance in pharmacogenomics lies in the study of how genetic factors influence responses to various therapeutic substances, leading to safer and more effective treatment strategies tailored to individual genetic backgrounds.
25) Solanki:
Solanki is a name, likely referring to an author or researcher in the field of pharmacogenomics who contributes to knowledge about personalized medicine. Researchers like Solanki play a vital role in advancing the scientific understanding of genetic influences on drug efficacy.
26) Account:
Account, in a pharmacogenomic context, refers to consideration or acknowledgement of genetic factors in individual drug response. Recognizing these accounts is vital for developing tailored treatment strategies that minimize adverse effects and maximize therapeutic success in diverse patient populations.
27) Reason:
Reason refers to a rationale or basis for actions or decisions. In pharmacogenomics, understanding the reasons behind genetic variability in drug metabolism aids healthcare providers in making informed choices about treatment options tailored to individual patient profiles.
28) Cloud:
Cloud, in pharmacogenomics, may refer to the use of cloud computing for data storage and analysis of genetic information. This technology helps researchers handle vast genomic datasets and facilitates real-time data-sharing and collaboration in personalized medicine research.
29) Mamsi (Mansi):
Mansi is likely a researcher or author involved in pharmacogenomic studies. As part of collaborative research efforts, Mansi contributes to understanding genetic influences on drug responses, ultimately aiming to improve personalized treatment strategies in medicine.
30) Fever:
Fever is a common symptom associated with various infections and diseases. In pharmacogenomics, genetic factors may influence how individuals respond to antipyretic medications, thus underscoring the significance of tailoring treatments based on individual genetic profiles to manage symptoms effectively.
31) Blood:
Blood carries essential components, including drugs and nutrients, throughout the body. In pharmacogenomics, analyzing blood samples can reveal genetic markers that predict drug response, thereby enabling healthcare providers to customize treatment plans based on an individual’s genetic makeup.
32) Study (Studying):
Study refers to the thorough investigation or examination of a subject. In pharmacogenomics, study designs include clinical trials and genetic research, aiming to link genetic variability with drug metabolism and response, ensuring personalized healthcare approaches for improved patient outcomes.
33) Diet:
Diet affects metabolism and has implications for drug efficacy and safety. In pharmacogenomics, understanding the interaction between diet and genetics can help identify personalized nutritional guidelines that optimize drug therapy and minimize possible adverse reactions for patients.
34) Pur:
Poor often characterizes suboptimal responses to medication therapy. In pharmacogenomics, identifying individuals with poor drug metabolism due to genetic variations helps practitioners adjust treatment strategies, ensuring medications are effective while minimizing the risk of adverse effects in those patients.
Other Science Concepts:
Discover the significance of concepts within the article: ‘Recent advances in pharmacogenomics for improved drug therapy.’. Further sources in the context of Science might help you critically compare this page with similair documents:
Adverse drug reaction, Therapeutic outcome, Allele frequency, Pharmacogenetic testing, Cytochrome P450, Genetic polymorphism, Next generation sequencing, Epigenetic modification, Pharmacokinetic, Precision medicine, Genetic landscape, FDA recommendation.